Kunena :: Тема: Posted by einzu1978 on 30.11.2016 9:43:40: tarceva egfr mutation (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by einzu1978 on 30.11.2016 9:43:40: tarceva egfr mutation

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by einzu1978 on 30.11.2016 9:43:40: tarceva egfr mutation

Страница:
1
2

ТЕМА: Posted by einzu1978 on 30.11.2016 9:43:40: tarceva egfr mutation

Posted by einzu1978 on 30.11.2016 9:43:40: tarceva egfr mutation 7 года 5 мес. назад #936

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
We showed that concurrent erlotinib with WBRT followed by maintenance erlotinib did not improve neurological PFS or OS in our patients with multiple brain metastases. The median neurological PFS and OS in this group were disappointingly low; 1.6 months and 3.4 months respectively, despite selecting only patients with age-modified RTOG RPA class I and II.
Table 3 lists all the adverse events that were at least possibly related to either vinorelbine or erlotinib throughout all treatment cycles. Toxicities were generally mild and the most commonly observed AEs were dermatological toxicities [dry skin, 100% (CSV), 93% (MSV); rash, 94% (CSV), 86% (MSV); pruritus, 88% (CSV), 86% (MSV)]. Acneiform rash, which is a common adverse effect of erlotinib, was common but none were above grade 2. Gastrointestinal toxicities were also common, with grade 1 to 2 diarrhoea occurring in 63% and 79% of patients in the CSV and MSV arms, respectively. Hematologic toxicity consisted of only neutropenia in the CSV arm, with two patients (13%) developing grade 3 neutropenia.
bzpp64.ru/index.php/forum/razdel-predloz...-15-tarceva-150-pret
Se debe advertir a los fumadores que deben dejar de fumar, ya que se sabe que fumar un cigarro induce CYP1A1 y CYP1A2, lo que disminuye la exposición a erlotinib en 50-60% (véase Dosis y vía de administración y Farmacocinética en poblaciones especiales).
The anti-inflammatory antibiotics like doxycycline and minocycline definitely help many patients with tarceva rash. Topic steroids can also help.
Adenocarcinoma and use of Tarceva
Tarceva Drug and Food Interactions
Tarceva-Drug Insights,2014
www.clubmycity.ru/forum/2-dobro-pozhalov...9-21-31-tarceva-epar
Erlotinib interactuando con Vacuna antituberculosa
Across the full study, including those without EGFR mutations, the median PFS was 6.5 months with gefitinib versus 7.5 months with erlotinib (adjusted HR, 1.125; 95% CI, 0.940-1.347). Median OS was 22.8 months with gefitinib versus 24.5 months with erlotinib (HR, 1.038; 95% CI, 0.833-1.294). The TTF was 5.6 versus 5.3 months, in the gefitinib and erlotinib arms, respectively (HR, 1.032; 95% CI, 0.866-1.231). The ORRs were 45.9% versus 44.1% and the DCRs were 70.9% versus 75.3%, for gefitinib and erlotinib, respectively.
Tausende Lungenkrebspatienten haben nun eine Chance auf ein längeres und besseres Leben dank Tarceva. Das neue Medikament wurde heute in der EU für Patienten mit lokal fortgeschrittenem oder metastatischem nichtkleinzelligem Bronchialkarzinom (NSCLC, Lungenkrebs) zugelassen, sofern mindestens eine vorgängige Chemotherapie erfolglos war.
* Tarceva had 2009 sales of $1.2 billion
• Advise females of reproductive potential to use highly effective contraception during treatment with Tarceva, and for at least 2 weeks after the last dose of Tarceva. • Advise patients to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, during treatment with Tarceva [see Use in Specific Populations (8.1 ), (8.6 )]. • Advise breast-feeding mothers to discontinue nursing while receiving Tarceva [see Use in Specific Populations (8.3 )].
Time on Tarceva when people have Loss Of Taste *:
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
www.ladies-news.ru/index.php/forum/obsuz...half-life-of-tarceva
Se observa una mejor respuesta y supervivencia sin progresión con Tarceva en los pacientes de un ensayo
Using erlotinib while you are pregnant can harm your unborn baby. Use an effective form of birth control to keep from getting pregnant. You should continue to use birth control during treatment and for 1 month after your last dose. If you think you have become pregnant while using the medicine, tell your doctor right away.
TradeFord.com is a growing Manufacturer Directory and B2B Marketplace connecting Global Erlotinib Price Importers, Exporters, Suppliers, Traders and Manufacturers at a reliable, common platform.
Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance. Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors. Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.Thr790Met alteration or MET activation. Genetic or pharmacological inhibition of AXL restored sensitivity to erlotinib in these tumor models. Increased expression of AXL and, in some cases, of its ligand GAS6 was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKIs. These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer.
Axl Promotes Erlotinib Resistance In Vitro and In Vivo
www.alym.38kir.ru/index.php/forum/dobro-...atment-drugs-tarceva
Structures of erlotinib and its O -demethylated metabolites.
Erlotinib HCl (OSI-744) EGFR-selective, IC50 =2 nM.
aum.com.ru/forum/10--/6117-posted-by-fra...tors-of-outcome#6117
Basch and his colleagues attempted a similar exercise in reviewing compendia recommendations for off-label use of Tarceva, which is approved to treat non-small cell lung cancer and pancreatic cancer. They found inconsistencies: Different compendia listed Tarceva for off-label use for different forms of cancer.
autoamalgama.ru/forum/zadajte-vopros/313...how-is-tarceva-given
. GFPC 0504 Team. Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504). BMC Cancer 2012 ; 12. 301. doi:10.1186/1471-2407-12-301
Tarceva: Package Insert and Label Information (Page 3 of 5)
Experimental: FOLFIRI with Erlotinib
Erlotinib, Hydrochloride Salt
Studies of cell models and profiling of clinical breast cancer material to reveal the mechanisms of resistance to anti-oestrogen therapy, and to tamoxifen in particular, have reported that this phenomenon can be associated with increased expression and signalling through erbB Type 1 growth factor receptors, notably the epidermal growth factor receptor (EGFR) and HER2. Further molecular studies have revealed an intricate interlinking between such growth factor receptor pathways and oestrogen receptor (ER) signalling. Inhibition of receptor tyrosine kinase activity involved in the EGFR signalling cascade forms the basis for the use of EGFR specific tyrosine kinase inhibitors exemplified by gefitinib (ZD1839, Iressa) and erlotinib (OSI-774, Tarceva). Such agents have proved promising in pre-clinical studies and are currently in clinical trials in breast cancer, where gefitinib has been studied more extensively to date. Here, we present an overview of the current development of gefitinib in clinical breast cancer. This includes results from our clinical breast cancer trial 1839IL/0057 that demonstrate the efficacy of gefitinib within ER-positive, tamoxifen-resistant patients with locally advanced/metastatic disease, where parallel decreases in EGFR signal transduction and the Ki67 (MIB1) proliferation marker can be detected as predicted from model system studies. We also consider trials examining combination treatment with gefitinib and anti-hormonal strategies that will begin to address the clinically important question of whether gefitinib can delay/prevent onset of anti-hormone resistance.
Other studies, such as BELIEF 17 (NCT01562028), and an ongoing in US trial (NCT01532089), are being carried out with the combination of erlotinib and bevacizumab with the primary objective of clarifying the role of this combination in the subgroup of EGFR -mutant NSCLC patients who also harbor the EGFR T790M mutation. 22
The purpose of this study is determine the safety of 5-fluorouracil, bevacizumab and erlotinib when administered in combination with external beam radiation therapy(Phase I portion) as well as to begin to collect information about whether this combination treatment is effective in treating(Phase II portion) patients with locally advanced rectal cancer.
dibor.com.ua/index.php/forum/13-och-umel...2-tarceva-statistics
The first indication of affinity of erlotinib for P-gp and BCRP was obtained in in vitro studies employing cells overexpressing BCRP and P-gp. A small but statistically significant difference in IC 50 was found between BCRP/Bcrp1- or P-gp-overexpressing and WT cell lines, which is apparently in contrast with the high rates of transport of erlotinib observed in Transwell experiments in Bcrp1- or P-gp-overexpressing cells. A first explanation for this discrepancy is that erlotinib is a growth factor inhibitor rather than a pure cytotoxic drug. This hypothesis is supported by the visual inspection of the plates obtained in the colony-forming assays, revealing a significant difference in growth characteristics of the colonies between cell lines and at applied different concentrations of the drug. At the same erlotinib concentration, the colonies were bigger in size in the MDR1- and BCRP-expressing cells compared with WT cells, and in the same cell line, colonies were smaller (but still composed of at least 50 cells) at higher erlotinib concentrations. Therefore, the difference in the IC 50 value only may not be fully representative for the effect of MDR1 or BCRP overexpression on the cytotoxicity of erlotinib.
Patients with stage IV NSCLC who have EGFR exon 19 or 21 mutations will randomized to received oral erlotinib 150mg or gefitinib 250mg once daily until disease progression or unacceptable toxicity. Method of direct DNA sequencing of tumor tissue is used to analysis EGFR mutation status of exons 18-21. The response will be evaluated by RECIST criteria first month,second month and then repeat every 3 months after the beginning of the treatment weeks.
Time on Tarceva when people have Exhaustion, Fatigue, Lethargy, Tiredness, Weariness *:
Response to erlotinib ( n = 29)
In contrast with erlotinib, gefitinib exhibited competitive inhibition against not only UGT1A1 but also UGT1A7, UGT1A9, and UGT2B7. The latter enzyme is involved in the metabolism of 35% drugs involved in glucuronidation of the top 200 prescribed drugs in the United States in 2002 (Williams et al. 2004 ). UGT1A9 and UGT1A7 are also involved in the glucuronidation of a number of drugs (Kiang et al. 2005 ). In addition, UGT1A1, UGT1A9, and UGT2B7 are expressed in both human liver and some extrahepatic tissues including the gastrointestinal tract, whereas UGT1A7 is present only in the esophagus, stomach, and lung (Kiang et al. 2005 ). UGTs in the gastrointestinal tract may contribute significantly to the first-pass metabolism of orally administered drugs that undergo glucuronidation. Our results showed that gefitinib might affect the glucuronidation and first-pass metabolism of more orally administered drugs than erlotinib.